Industry: Pharmaceuticals, Biotechnology
CardioVascular BioTherapeutics Inc. (CVBT) is a biopharmaceutical company, headquartered in Las Vegas, Nevada, currently focused on developing new drugs for the treatment of cardiovascular disease. Our protein drug candidate, CardioVascu-GrowÔ, is designed to facilitate growth of new blood vessels in the heart and other tissues and organs with impaired vascular systems. In two separate clinical trials in Germany in the mid-1990s that Dr. Thomas J. Stegmann conducted, a protein identical in structure to CardioVascu-GrowÔ prompted the growth of new blood vessels in the heart and an increased pumping capacity of the heart in the patients treated. We are now working to confirm the medical benefits of this protein drug candidate through human clinical trials authorized by the ( www.cvbt.com )
Cardiovascular Biotherapeutics, Inc.
1635 Village Center Circle Suite 250
Las Vegas, Nevada 89134
USA
Tel: (702) 248-1174